Early Acute Lung Injury: Prospective Evaluation Prior to Respiratory Failure

早期急性肺损伤：呼吸衰竭前的前瞻性评估

• 批准号: 7936130
• 负责人: Joseph Eric Levitt
• 金额: $ 13.45万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7936130
• 关键词: Accident and Emergency department; Acute; Acute Lung Injury; Acute respiratory failure; Admission activity; Adrenergic Agonists; Adult; Agonist; Albuterol; Alveolar; American; Bilateral; Biological Markers; Biological Markers; Breathing; Characteristics; Chest; Clinical; Clinical Trials; Comorbidity; Consensus; Development; Diagnosis; Disease; Disease Progression; Dyspnea; Enrollment; Environmental air flow; Epidemiology; Epithelial; European; Evaluation; Extravascular Lung Water; Floods; Future; Gases; Goals; Heart Atrium; Hospitalization; Hospitals; Hour; Hypertension; Hypoxia; IL8 gene; Incidence Study; Inflammation; Injury; Instruction; Intercellular adhesion molecule 1; Intravenous; Investigation; Left; Logistic Regressions; Lung; Lung Compliance; Lung Inflammation; Measurement; Measures; Mechanical ventilation; Medicine; Morbidity - disease rate; Multivariate Analysis; National Heart, Lung, and Blood Institute; Outcome; Outcome Measure; Oxygen; Pathogenesis; Pathway interactions; Patients; Phase; Placebos; Plasma; Predictive Value; Principal Investigator; Prior Therapy; Pulmonary Surfactant-Associated Protein D; Randomized; Randomized Clinical Trials; Regression Analysis; Research; Respiratory Failure; Risk; Role; Screening procedure; Sepsis; Serum; Services; Severity of illness; Specificity; Stratification; Syndrome; Testing; Therapeutic; Therapeutic Effect; Time; Tube; VWF gene; Wit; abstracting; aerosolized; clinical practice; cohort; demographics; endotracheal; evidence base; face mask; high risk; improved; inflammatory marker; insight; lung injury; meetings; mortality; outcome forecast; pressure; prognostic; prospective; respiratory; response; secondary outcome; symposium

DESCRIPTION (provided by applicant): Acute lung injury (ALI) is a syndrome of acute hypoxic respiratory failure due to pulmonary and non-pulmonary insults and is a major cause of morbidity and mortality. Despite two decades of targeted investigation by the NHLBI, little is known about ALI prior to progression to respiratory failure requiring mechanical ventilation. Accordingly, the aims of this research plan are to: 1) prospectively identify independent predictors of progression to ALI requiring mechanical ventilation and establish a clinical definition of early ALI; 2) evaluate the pathogenetic role of biologic markers of inflammation and lung injury and their value for refining risk stratification of patients at risk for progression to ALI, and 3) test the potential therapeutic value of an aerosolized beta-2 agonist in patients with early ALI. In SPECIFIC AIM 1 will identify cases of potential early ALI by screening chest radiographs of all adult emergency department and medicine service admissions. Patients admitted to the hospital with bilateral opacities on chest radiograph not due to isolated left atrial hypertension will be followed for progression to ALI during their hospitalization. Clinical characteristics (demographics, diagnoses, comorbidities, vital signs, and Borg dyspnea scores) will be recorded for the first 72 hours of admission. Independent predictors of progression to ALI will be determined by multivariate logistic regression and incorporated into a clinical definition of early ALI. In SPECIFIC AIM 2, plasma levels of biomarkers (IL-8, sTNFr-1, vWF, ICAM-1, SP-D and RAGE) representing distinct pathways contributing to acute lung injury will be measured at time 0 and 24 hours after study enrollment. Biomarkers will be analyzed by multivariate regression analysis to assess their value for stratifying patients at risk for progression to ALI and provide mechanistic insight into the pathogenesis of early ALI. In SPECIFIC AIM 3 I will conduct a randomized clinical trial of aerosoUzed albuterol vs. placebo in patients with early ALI. The primary endpoint will be the Pa02 / Fi02 on day 4 of treatment. Secondary outcome measures will be rate of progression to ALI and change in plasma biologic marker levels. This will be a first-of-its-kind trial to establish that patients with early ALI can be identified and treatment can be initiated prior to need for mechanical ventilation. RELEVANCE (See instructions): Following the paradigm of early goal-directed therapy for severe sepsis, clinical benefit may derive from identifying patients with early ALI and initiating treatment prior to the need for mechanical ventilation (and therefore prior to meeting current study entry criteria). Establishing evidence based clinical definition of early ALI will facilitate identification and risk stratification of subjects for enrollment in future clinical trials. (End of Abstract)

描述（由申请人提供）：急性肺损伤（ALI）是由肺和非肺损伤引起的急性缺氧性呼吸衰竭综合征，是发病率和死亡率的主要原因。尽管NHLBI进行了20年的有针对性的研究，但在进展为需要机械通气的呼吸衰竭之前，对ALI知之甚少。因此，本研究计划的目的是：1）前瞻性地确定需要机械通气的ALI进展的独立预测因素，并建立早期ALI的临床定义; 2）评估炎症和肺损伤生物标志物的发病作用及其对改善有进展为ALI风险的患者的风险分层的价值，以及3）测试雾化β-2激动剂在患有早期ALI的患者中的潜在治疗价值。在具体目标1将确定潜在的早期急性肺损伤的情况下，通过筛选胸片的所有成人急诊科和医疗服务入院。住院期间，将对胸部X线片显示双侧阴影（非孤立性左心房高压所致）的患者进行随访，以确定是否进展为ALI。将记录入院前72小时的临床特征（人口统计学、诊断、合并症、生命体征和博格呼吸困难评分）。将通过多变量逻辑回归确定进展为ALI的独立预测因素，并将其纳入早期ALI的临床定义中。在SPECIFIC AIM 2中，将在研究入组后0和24小时测量代表导致急性肺损伤的不同途径的生物标志物（IL-8、sTNFr-1、vWF、ICAM-1、SP-D和TNF-α）的血浆水平。将通过多变量回归分析对生物标志物进行分析，以评估其对有进展为ALI风险的患者进行分层的价值，并提供对早期ALI发病机制的机制见解。在SPECIFIC AIM 3中，我将在早期ALI患者中进行一项雾化沙丁胺醇与安慰剂的随机临床试验。主要终点是治疗第4天的Pa 02/Fi 02。次要结局指标将是进展为ALI的速率和血浆生物标志物水平的变化。这将是一项首创的试验，以确定早期ALI患者可以被识别，并且可以在需要机械通气之前开始治疗。相关性（参见说明）：遵循针对严重脓毒症的早期目标导向治疗的范例，临床获益可能来自于识别早期ALI患者并在需要机械通气之前（因此在满足当前研究入选标准之前）开始治疗。建立早期ALI的循证临床定义将有助于识别和风险分层受试者，以便在未来的临床试验中招募。(End摘要）